Medical/Pharmaceuticals
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting
* CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the latest safety and efficacy of CS5001 as a monotherapy for patients with advanced lymphomas. * CS5001 is well tolerated in heavily...
2024-12-09 08:20
4316
Innovent Presents Updated Data From Innovative Anti-CLDN18.2 ADC (IBI343) Phase 1 Study in Patients with Advanced Pancreatic Cancer at the ESMO Asia Congress 2024
SAN FRANCISCO and SUZHOU, China, Dec. 9, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...
2024-12-09 08:00
4588
EpiVax Drives Immunogenicity Innovation in 2024: Year in Review
PROVIDENCE, R.I., Dec. 7, 2024 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by scientific innovation, service diversification, and corporate growth. This year, EpiVax expanded the b...
2024-12-07 11:30
5247
Singapore's IMAGINE AI: Largest Global Gathering to Shape the Future of Healthcare with AI Innovations
SINGAPORE, Dec. 6, 2024 /PRNewswire/ -- IMAGINE AI is the largest calendar event inSingapore that brings together the brightest minds in healthcare and artificial intelligence to explore the transformative potential of AI in healthcare. Hosted at the Marina Bay Sands Expo & Convention Centre, thi...
2024-12-06 10:41
11488
SD Biosensor Signs Tripartite MOU for R&D of New Products for Extensively Drug-Resistant Tuberculosis with Japan's RIT/JATA and Korea's International Tuberculosis Research Center
* SD Biosensor strengthens its new product lineup with the POC molecular diagnostic platform M10 * Early detection of patients is expected to contribute to the eradication of tuberculosis in high-risk Asian countries SEOUL, South Korea, Dec. 6, 2024 /PRNewswire/ -- SD Biosensor, Inc. (KQ13731...
2024-12-06 09:00
3964
Alamar Biosciences Establishes Commercial Presence in APAC Region with First ARGO HT Install at Hong Kong Center for Neurodegenerative Diseases
FREMONT, Calif., Dec. 6, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is proud to announce its commercial presence in theAsia Pacific (APAC) region with the installation of the ARGO™ HT System, an advanced ultra-sens...
2024-12-06 08:07
4028
KANEKA UBIQUINOL™ AWARDED PRESTIGIOUS COMPLEMENTARY MEDICINES AUSTRALIA RAW MATERIAL SUPPLIER OF THE YEAR AWARD 2024
SYDNEY, Dec. 6, 2024 /PRNewswire/ -- Kaneka Ubiquinol™ has been awarded the
covetedRaw Material Supplier of the Year Award 2024 at the Complementary
Medicines Australia (CMA) Awards, held inSydney this evening.
2024-12-06 06:10
3992
AtomVie Global Radiopharma Appoints Dr. Pratibhash Chattopadhyay as Chief Business Officer to Accelerate Growth and Strengthen Leadership
HAMILTON, ON, Dec. 5, 2024 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, is pleased to announce the appointment of Dr. Pratibhash (Bosh) Chattopadhyay as Chief Business Officer. Dr. Chattopadhyay brings over 25 years of commercial and technical ...
2024-12-05 22:00
1930
Field Medical's FieldForce™ Ablation System Earns FDA TAP Pilot Acceptance and Breakthrough Device Designation for the Treatment of Ventricular Tachycardia.
* First and only contact force pulsed field ablation (PFA) system engineered to revolutionize care for the hundreds of thousands at risk of death from ventricular tachycardia (VT). * FDA's TAP Pilot and Breakthrough Device Designation are awarded to medical devicesthat could provide more effe...
2024-12-05 21:03
2978
LifeSignals Receives EU MDR Certification for UbiqVue™ 2A Multiparameter System
Cloud-Based System, Featuring Wearable Biosensor with Chest-Based SpO2, Enables Active Patient Monitoring Across Hospital and Out-of-hospital Care Settings * Replaces time-consuming manual spot checking with continuous, near real-time active patient monitoring * Web-based system displays mult...
2024-12-05 20:00
2545
Cambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator Manufacturing
EAST RUTHERFORD, N.J., Dec. 5, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has signed an agreement with Eli Lilly and Company (Lilly) to deliver accelerated access to clinical development capabilities for Lilly...
2024-12-05 19:00
3829
NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis
MILAN, Dec. 5, 2024 /PRNewswire/ -- NTC, an international R&D focused pharmaceutical company headquartered inItaly, presents positive results from Phase II MIRAKLE study, a multicentre, randomized, blinded-assessor, phase II non-inferiority study evaluatingthe efficacy and tolerability of NTC014 ...
2024-12-05 19:00
3531
Cao Thang International Eye Hospital - Marking a footprint on the map of global ophthalmology
HO CHI MINH CITY, Vietnam, Dec. 5, 2024 /PRNewswire/ -- On November 10, 2024, Cao Thang International Eye Hospital was proudly certified to be an official membership with the World Association of Eye Hospitals (WAEH) at the 18th annual meeting which was held inChina. Cao Thang International Eye ...
2024-12-05 18:35
3151
CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial
MELBOURNE, Australia, Dec. 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has successfully completed its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). Key...
2024-12-05 11:59
3262
Former CSL CEO Paul Perreault appointed strategic adviser to Microbio
Establishing sepsis diagnostic InfectID™ as the new standard of care BRISBANE, Australia, Dec. 5, 2024 /PRNewswire/ -- Microbio Ltd, the Australian pathogen diagnostics company specialising in innovative molecular diagnostic solutions, has today announced the appointment ofPaul Perreault as a st...
2024-12-05 06:30
3320
LBB Specialties and Clariant Partner to Distribute High-Quality Pharmaceutical Grade PEGs for Ophthalmic Applications
NORWALK, Conn., Dec. 5, 2024 /PRNewswire/ -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, announced a strategic partnership with Clariant, a global leader in specialty chemical manufacturing. Through this collaboration, LBB Specialties will ...
2024-12-05 04:02
2400
CU Medicine invents a non-invasive technology for people with uninvestigated bowel symptoms
HONG KONG, Dec. 4, 2024 /PRNewswire/ -- The Chinese University of Hong Kong's Faculty of Medicine (CU Medicine) has, for the first time, discovered novel microbial signatures associated with inflammation of the gastrointestinal (GI) tract and transformed such signatures into clinically applicable...
2024-12-04 22:26
4714
Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved mapping and dual energy ablation catheter
AUSTIN, Texas, Dec. 4, 2024 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first in the nation to use an all-in-one high-density mapping and dual energy ablation catheter for the treatment of persistent atria...
2024-12-04 10:07
3778
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
* Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission. * In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and ...
2024-12-04 09:10
3500
Exciting Offers Await at the 2024 Hong Kong Brands and Products Expo: Herbalgy Presents Exclusive Deals & Debuting "Yick Kee Balanced Tea Limited" Health Tea Bags!
Exclusive Discounts Up to 38% and Limited Edition Gifts HONG KONG, Dec. 4, 2024 /PRNewswire/ -- As December approaches, the highly anticipated Hong Kong Brands and Products Expo is just around the corner. Herbalgy Pharmaceutical Limited, a proud participant in this annual shopping event for many...
2024-12-04 09:00
3151
Week's Top Stories
Most Reposted
Visa returns as title sponsor for 2026 MAMA AWARDS; Visa Presale registration begins 13 October
[Picked up by 310 media titles]
2026-10-13 10:00
Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 279 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 275 media titles]
2026-10-09 13:21DayOne Upsizes Malaysia Financing to US$7.2 Billion; Total Billings Surpass 1GW and Bookings Reach 2.3GW
[Picked up by 269 media titles]
2026-10-14 18:01Ampotech and Buskowitz Energy Collaborate to Deliver Integrated Energy Solutions Combining Energy Efficiency, Solar and Battery Storage
[Picked up by 263 media titles]
2026-10-14 09:30
Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
16013
LEIFRAS Co., Ltd. Reports First Half of Fiscal Year 2026 Financial Results
2026-10-08 09:50
14128
XPENG G9L Completes First Production Trial in Europe
2026-10-08 07:33
13630
